Estrella Immunopharma announced on May 29, 2025, that the first patient has been dosed in the second cohort of its dose escalation study. This is part of the Phase I/II STARLIGHT-1 trial for EB103.
The STARLIGHT-1 trial is evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, for patients with Advanced B-Cell Non-Hodgkin’s Lymphomas. Dosing in a higher cohort follows the successful completion of the first dose cohort.
This event signifies continued operational progress in the clinical development of EB103. It moves the trial forward in exploring the safety and efficacy of the therapy at increased dose levels.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.